Palisade Bio Inc (PALI) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.66 (-2.35%), Market cap $0.31B, P/E ratio 15.08, 52-week low–high $0.54 ~ $2.80.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-D
Financial statements, price targets, institutional (13F) holdings and related news for Palisade Bio Inc are updated in real time on BlackAll Trade.
Palisade Bio Inc trades at $1.66 (-2.35%). Real-time quotes and charts are available on BlackAll Trade.
Palisade Bio Inc has a market cap of about $0.31B. Its P/E ratio is 15.08.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the